Meridian Bioscience (VIVO) Tops Q2 EPS by 35c
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $5.87 +7.71%
Financial Fact:
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC: -84.07M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Financial Fact:
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC: -84.07M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Meridian Bioscience (NASDAQ: VIVO) reported Q2 EPS of $0.67, $0.35 better than the analyst estimate of $0.32. Revenue for the quarter came in at $111.2 million versus the consensus estimate of $83.29 million.
GUIDANCE:
Meridian Bioscience sees FY2022 EPS of $1.30-$1.40, versus the consensus of $1.37. Meridian Bioscience sees FY2022 revenue of $330-345 million, versus the consensus of $337 million.
For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- AeroVironment restates quarterly financials, citing $89M goodwill error
- Sun Communities names Ileana McAlary as general counsel and EVP
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
